Peptide
Cardiogen
SaveA Khavinson bioregulator tripeptide (Ala-Glu-Asp-Arg) designed to support cardiac tissue function and repair.
Quick verdict
Limited to small Russian studies. No international clinical trials or regulatory approval outside Russia.
Evidence score
12/ 100
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Published data come from the Khavinson research group. Claims of cardiomyocyte gene expression modulation are not independently validated.
Benefits
- Claimed cardioprotective effects in Russian studies
- Oral peptide bioregulator format
Dosage notes
Russian protocols: 5–10 mg/day orally for 10–30 day courses.
Side effects
- Not well characterized
- Theoretical hypotension
Who should be cautious
Not approved outside Russia. No independent safety or efficacy data.
What this page cannot tell you
All evidence originates from a single research group without independent replication.
Leaderboard scores
- Longevity15
Write a review
Sign in to write a review.